GLP-1 RECEPTOR AGONISTS IN CHRONIC KIDNEY DISEASE: NEPHROPROTECTION BEYOND GLYCEMIC CONTROL - A REVIEW OF CURRENT LITERATURE
DOI:
https://doi.org/10.31435/ijitss.2(50).2026.6653Keywords:
GLP-1 Receptor Agonist, Chronic Kidney Disease, Glycemic Control, Kidney Failure, Nephroprotective EffectsAbstract
Background: Chronic Kidney Disease (CKD) is currently one of the major global health burdens and the number of people affected by this disease is still rising. CKD is strongly associated with type 2 diabetes mellitus (T2DM), obesity and cardiovascular diseases. Despite the fact that glucagon-like-peptide-1 receptor agonists were primarily developed as glucose-lowering agents, accumulating evidence suggests that their benefits extend beyond glycemic control and include significant renoprotective effects.
Aim: This review synthesises current evidence on the nephroprotective effects of GLP-1 receptor agonists in patients with CKD with emphasis on clinical trials outcomes and future therapeutic perspectives.
Materials and Methods: A narrative review of current literature was conducted in PubMed, Google Scholar, and Scopus. Relevant randomized controlled trials, meta-analyses, and recent review articles published between 2019 and 2026 were analyzed.
Results: GLP-1 receptor agonists expend nephroprotective effects through multiple pathways, including reduction of systemic inflammation, oxidative stress, endothelial dysfunction, albuminuria and intraglomerular hypertension. Additional benefits arise from weight reduction, blood pressure lowering and cardiovascular protection. Clinical trials such as LEADER, SUSTAIN-6, REWIND, and particularly the FLOW trial demonstrated significant reductions in renal composite outcomes and slower decline in estimated glomerular filtration rate (eGFR). The FLOW trial provided the first dedicated evidence that semaglutide significantly reduces the risk of kidney disease progression and cardiovascular death in patients with T2DM and CKD.
Conclusions: Current evidence suggests that GLP-1 receptor agonists represent an emerging nephroprotective therapy with benefits extending far beyond glycemic control. Their pleiotropic effects may position GLP-1 RAs as an important component of future cardio–renal–metabolic management strategies in CKD patients. Further studies are needed to clarify their role in non-diabetic CKD and advanced kidney disease.
References
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. (2024). KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International, 105(4 Suppl), S117–S314. https://doi.org/10.1016/j.kint.2023.10.018
Jager, K. J., Kovesdy, C., Langham, R., Rosenberg, M., Jha, V., & Zoccali, C. (2019). A single number for advocacy and communication—Worldwide more than 850 million individuals have kidney diseases. Kidney International, 96(5), 1048–1050. https://doi.org/10.1016/j.kint.2019.07.012
Bikbov, B., Purcell, C. A., Levey, A. S., et al. (2020). Global, regional, and national burden of chronic kidney disease, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. The Lancet, 395(10225), 709–733. https://doi.org/10.1016/S0140-6736(20)30045-3
Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017). Diabetic kidney disease: Challenges, progress, and possibilities. Clinical Journal of the American Society of Nephrology, 12(12), 2032–2045. https://doi.org/10.2215/CJN.11491116
Tuttle, K. R., Bakris, G. L., Bilous, R. W., et al. (2014). Diabetic kidney disease: A report from an ADA Consensus Conference. Diabetes Care, 37(10), 2864–2883. https://doi.org/10.2337/dc14-1296
Brenner, B. M., Cooper, M. E., de Zeeuw, D., et al. (2001). Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New England Journal of Medicine, 345(12), 861–869. https://doi.org/10.1056/NEJMoa011161
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., et al. (2017). GLP-1 and the kidney: From physiology to pharmacology and outcomes in diabetes. Nature Reviews Nephrology, 13(10), 605–628. https://doi.org/10.1038/nrneph.2017.123
Drucker, D. J. (2018). Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism, 27(4), 740–756. https://doi.org/10.1016/j.cmet.2018.03.001
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes—State-of-the-art. Molecular Metabolism, 46, 101102. https://doi.org/10.1016/j.molmet.2020.101102
Mann, J. F. E., Ørsted, D. D., Brown-Frandsen, K., et al. (2017). Liraglutide and renal outcomes in type 2 diabetes. New England Journal of Medicine, 377(9), 839–848. https://doi.org/10.1056/NEJMoa1616011
Marso, S. P., Bain, S. C., Consoli, A., et al. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 375(19), 1834–1844. https://doi.org/10.1056/NEJMoa1607141
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., et al. (2019). Dulaglutide and renal outcomes in type 2 diabetes: An exploratory analysis of the REWIND randomised placebo-controlled trial. The Lancet, 394(10193), 131–138. https://doi.org/10.1016/S0140-6736(19)31150-X
Tuttle, K. R., Lakshmanan, M. C., Rayner, B., et al. (2018). Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): A multicentre, open-label, randomised trial. The Lancet Diabetes & Endocrinology, 6(8), 605–617. https://doi.org/10.1016/S2213-8587(18)30104-9
Perkovic, V., Tuttle, K. R., Rossing, P., et al. (2024). Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. New England Journal of Medicine, 391(2), 109–121. https://doi.org/10.1056/NEJMoa2403347
American Diabetes Association Professional Practice Committee. (2025). Standards of care in diabetes—2025. Diabetes Care, 48(Suppl 1). https://doi.org/10.2337/dc25-SINT
Holst, J. J. (2007). The physiology of glucagon-like peptide 1. Physiological Reviews, 87(4), 1409–1439. https://doi.org/10.1152/physrev.00034.2006
Drucker, D. J. (2018). Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism, 27(4), 740–756. https://doi.org/10.1016/j.cmet.2018.03.001
Müller, T. D., Finan, B., Bloom, S. R., et al. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 30, 72–130. https://doi.org/10.1016/j.molmet.2019.09.010
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes—State-of-the-art. Molecular Metabolism, 46, 101102. https://doi.org/10.1016/j.molmet.2020.101102
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., et al. (2017). GLP-1 and the kidney: From physiology to pharmacology and outcomes in diabetes. Nature Reviews Nephrology, 13(10), 605–628. https://doi.org/10.1038/nrneph.2017.123
Kodera, R., Shikata, K., Kataoka, H. U., Takatsuka, T., Miyamoto, S., Sasaki, M., et al. (2011). Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia, 54(4), 965–978. https://doi.org/10.1007/s00125-010-2028-x
Knudsen, L. B., & Lau, J. (2019). The discovery and development of liraglutide and semaglutide. Frontiers in Endocrinology, 10, 155. https://doi.org/10.3389/fendo.2019.00155
Campbell, J. E., & Drucker, D. J. (2013). Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metabolism, 17(6), 819–837. https://doi.org/10.1016/j.cmet.2013.04.008
Ruiz-Ortega, M., Rayego-Mateos, S., Lamas, S., Ortiz, A., & Rodrigues-Diez, R. R. (2020). Targeting inflammation to treat chronic kidney disease. Nature Reviews Nephrology, 16(12), 689–710. https://doi.org/10.1038/s41581-020-00320-5
Forbes, J. M., & Cooper, M. E. (2013). Mechanisms of diabetic complications. Physiological Reviews, 93(1), 137–188. https://doi.org/10.1152/physrev.00045.2011
Kovesdy, C. P., Furth, S. L., & Zoccali, C. (2017). Obesity and kidney disease: Hidden consequences of the epidemic. Kidney International, 91(2), 260–262. https://doi.org/10.1016/j.kint.2016.10.019
Ouchi, N., Parker, J. L., Lugus, J. J., & Walsh, K. (2011). Adipokines in inflammation and metabolic disease. Nature Reviews Immunology, 11(2), 85–97. https://doi.org/10.1038/nri2921
Hall, J. E., do Carmo, J. M., da Silva, A. A., Wang, Z., & Hall, M. E. (2015). Obesity-induced hypertension: Interaction of neurohumoral and renal mechanisms. Circulation Research, 116(6), 991–1006. https://doi.org/10.1161/CIRCRESAHA.116.305697
D’Agati, V. D., Chagnac, A., de Vries, A. P. J., Levi, M., Porrini, E., Herman-Edelstein, M., et al. (2016). Obesity-related glomerulopathy: Clinical and pathologic characteristics and pathogenesis. Nature Reviews Nephrology, 12(8), 453–471. https://doi.org/10.1038/nrneph.2016.75
Tonneijck, L., Muskiet, M. H. A., Smits, M. M., van Bommel, E. J. M., Heerspink, H. J. L., van Raalte, D. H., et al. (2017). Glomerular hyperfiltration in diabetes: Mechanisms, clinical significance, and treatment. Journal of the American Society of Nephrology, 28(4), 1023–1039. https://doi.org/10.1681/ASN.2016060666
Yin, Q., Zhang, Y., Zheng, W., et al. (2023). GLP-1 receptor agonists attenuate renal fibrosis and inflammation through modulation of TGF-β signaling pathways: Experimental evidence. Frontiers in Pharmacology, 14, 1187142. https://doi.org/10.3389/fphar.2023.1187142
Sattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., et al. (2021). Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of randomised trials. The Lancet Diabetes & Endocrinology, 9(10), 653–662. https://doi.org/10.1016/S2213-8587(21)00203-5
Stenvinkel, P., Ketteler, M., Johnson, R. J., Lindholm, B., Pecoits-Filho, R., Riella, M., et al. (2005). IL-10, IL-6, and TNF-α: Central factors in the altered cytokine network of chronic kidney disease. Kidney International, 67(4), 1216–1233. https://doi.org/10.1111/j.1523-1755.2005.00200.x
Kodera, R., Shikata, K., Kataoka, H. U., Takatsuka, T., Miyamoto, S., Sasaki, M., et al. (2011). Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia, 54(4), 965–978. https://doi.org/10.1007/s00125-010-2028-x
Lee, Y. S., & Jun, H. S. (2016). Anti-inflammatory effects of GLP-1-based therapies beyond glucose control. Mediators of Inflammation, 2016, 3094642. https://doi.org/10.1155/2016/3094642
Yaribeygi, H., Atkin, S. L., Simental-Mendía, L. E., & Sahebkar, A. (2020). Molecular mechanisms by which GLP-1 receptor agonists confer renoprotection. Journal of Cellular Physiology, 235(12), 9073–9084. https://doi.org/10.1002/jcp.29775
Crajoinas, R. O., Oricchio, F. T., Pessoa, T. D., Pacheco, B. P. M., Lessa, L. M. A., Malnic, G., et al. (2011). Mechanisms mediating the diuretic and natriuretic actions of GLP-1 in the kidney. American Journal of Physiology-Renal Physiology, 301(2), F355–F363. https://doi.org/10.1152/ajprenal.00729.2010
Loeffler, I., & Wolf, G. (2014). Transforming growth factor-beta and the progression of renal disease. Nephrology Dialysis Transplantation, 29(Suppl 1), i37–i45. https://doi.org/10.1093/ndt/gft267
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., et al. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). New England Journal of Medicine, 375(4), 311–322. https://doi.org/10.1056/NEJMoa1603827
Nystrom, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., et al. (2004). Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. American Journal of Physiology-Endocrinology and Metabolism, 287(6), E1209–E1215. https://doi.org/10.1152/ajpendo.00237.2004
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
Mann, J. F. E., Buse, J. B., Idorn, T., et al. (2024). Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nature Medicine, 30(10), 2849–2856. https://doi.org/10.1038/s41591-024-03133-0
Pratley, R. E., Tuttle, K. R., Rossing, P., et al. (2024). Effects of semaglutide on heart failure outcomes in diabetes and chronic kidney disease in the FLOW trial. Journal of the American College of Cardiology, 84(17), 1615–1628. https://doi.org/10.1016/j.jacc.2024.08.004
Mann, J. F. E., Fonseca, V. A., Mosenzon, O., et al. (2021). Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis. Diabetes, Obesity and Metabolism, 23(9), 2058–2066. https://doi.org/10.1111/dom.14443
Kristensen, S. L., Rørth, R., Jhund, P. S., et al. (2019). Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: Systematic review and meta-analysis of cardiovascular outcome trials. The Lancet Diabetes & Endocrinology, 7(10), 776–785. https://doi.org/10.1016/S2213-8587(19)30249-9
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. (2024). KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International, 105(Suppl 4S), S117–S314. https://doi.org/10.1016/j.kint.2023.10.018
American Diabetes Association Professional Practice Committee. (2025). Standards of care in diabetes—2025. Diabetes Care, 48(Suppl 1). https://doi.org/10.2337/dc25-SINT
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Anna Mamach, Aleksandra Woźniak, Patrycja Sobantka, Szymon Mokrzecki, Matylda Król, Katarzyna Aleksandrowicz, Zofia Grodzka, Mateusz Meszka, Ewa Bełc, Karolina Brzezińska
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
